4,813 results match your criteria Alopecia Areata


Alemtuzumab-induced Alopecia areata - a case report and systematic literature review of adverse events associated with Alemtuzumab.

J Dtsch Dermatol Ges 2021 May 10. Epub 2021 May 10.

Klinik für Hautkrankheiten, Universitätsklinikum Münster [Dermatology clinic, University Hospital Münster, Germany.

Alemtuzumab is currently approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Despite the efficacy of this therapy several side effects in the skin have been noted during or after infusion including vitiligo, alopecia areata, malignant skin tumors and infections. Awareness of these effects and their treatment is of essential interdisciplinary importance. Read More

View Article and Full-Text PDF

Alopecia areata is not a risk factor for heart diseases: A 10-year retrospective cohort study.

PLoS One 2021 7;16(5):e0250216. Epub 2021 May 7.

Department of Dermatology, Ajou University School of Medicine, Suwon, Korea.

Alopecia areata (AA) is an autoimmune skin disease caused by chronic inflammation of hair follicles. Chronic inflammatory skin diseases such as psoriasis and lupus erythematosus can increase the risk of cardiovascular diseases. However, the relationship between AA and heart diseases (HDs) remains unclear. Read More

View Article and Full-Text PDF

Clinico-Epidemiological Profile of Childhood Alopecia Areata Along with Dermoscopic Correlation: A Cross-Section, Observational Study.

Indian Dermatol Online J 2021 Mar-Apr;12(2):250-257. Epub 2021 Mar 2.

Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India.

Background: Childhood alopecia areata (AA) is a common cause of dermatologic consultation; however, data is scarce in the present set-up.

Objectives: To evaluate the clinico-epidemiological profile of childhood AA along with dermoscopic correlation.

Methods: We conducted a cross-sectional study including 50 new cases of childhood AA for 1 year. Read More

View Article and Full-Text PDF

Treatment of Pediatric Alopecia Areata: A Systematic Review.

J Am Acad Dermatol 2021 Apr 30. Epub 2021 Apr 30.

Department of Dermatology, University of California Davis, Sacramento, CA, USA; Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USA. Electronic address:

Background: Alopecia areata (AA) is an autoimmune, non-scarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking.

Methods: We conducted a systematic review on the PubMed database in October 2019 for all published articles involving patients <18 years old. Read More

View Article and Full-Text PDF

Mesenchymal Stem Cells Antagonize IFN-Induced Proinflammatory Changes and Growth Inhibition Effects via Wnt/β-Catenin and JAK/STAT Pathway in Human Outer Root Sheath Cells and Hair Follicles.

Int J Mol Sci 2021 Apr 27;22(9). Epub 2021 Apr 27.

Department of Dermatology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Korea.

Mesenchymal stem cell therapy (MSCT) has been shown to be a new therapeutic option for treating alopecia areata (AA). Outer root sheath cells (ORSCs) play key roles in maintaining the hair follicle structure and supporting the bulge area. In human ORSCs (hORSCs), the mechanism for this process has not been extensively studied. Read More

View Article and Full-Text PDF

Dexamethasone-Loaded Lipomers: Development, Characterization, and Skin Biodistribution Studies.

Pharmaceutics 2021 Apr 11;13(4). Epub 2021 Apr 11.

Topical & Oral Development R+D Reig Jofre Laboratories, 08970 Barcelona, Spain.

Follicular targeting has gained more attention in recent decades, due to the possibility of obtaining a depot effect in topical administration and its potential as a tool to treat hair follicle-related diseases. Lipid core ethyl cellulose lipomers were developed and optimized, following which characterization of their physicochemical properties was carried out. Dexamethasone was encapsulated in the lipomers (size, 115 nm; polydispersity, 0. Read More

View Article and Full-Text PDF

A Nationwide Multicenter Cross-Sectional Questionnaire Study On The Use of Non-dermatologic Facilities Among Patients With Hair Loss.

J Eur Acad Dermatol Venereol 2021 Apr 29. Epub 2021 Apr 29.

Department of Dermatology, Eunpyeong St. Mary's Hospital, Seoul, Korea.

Patients with hair loss often use alternative therapy or visit different non-dermatologist providers (NDPs) such as traditional medicine specialists, estheticians, and general practitioners without an accurate diagnosis of alopecia.(1-3) Since alopecia is often etiologically complex, there has been a rising concern regarding NDPs, who are not board-certified dermatologists, caring for such patients.(4, 5) Therefore, we performed a nationwide questionnaire study on the use of non-dermatologic facilities (NDFs) among patients with hair loss to better understand the pattern of NDF use. Read More

View Article and Full-Text PDF

Topical tofacitinib for the treatment of alopecia areata affecting facial hair.

Br J Dermatol 2021 Apr 29. Epub 2021 Apr 29.

Sinclair Dermatology, East Melbourne, Victoria, Australia.

Alopecia areata (AA) is a common autoimmune condition which can affect any hair-bearing site. Recent studies have demonstrated the effectiveness of Janus kinase inhibitors (JAKis) in the treatment of AA. Most studies documenting response of AA affecting facial hair to JAKi therapy involve oral administration due to extensive concomitant scalp involvement. Read More

View Article and Full-Text PDF

Association between Alopecia Areata and Comorbid Allergies: Implications for Its Clinical Course.

Ann Dermatol 2020 Dec 11;32(6):523-525. Epub 2020 Nov 11.

Department of Dermatology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.

View Article and Full-Text PDF
December 2020

Analysis of Microscopic Examination of Pulled Out Hair in Telogen Effluvium Patients.

Ann Dermatol 2020 Apr 11;32(2):141-145. Epub 2020 Mar 11.

Department of Dermatology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

Background: Telogen effluvium (TE) is characterized by massive hair shedding and results from an abrupt conversion of anagen to telogen. Differentiation of TE with other hair disorders showing massive hair shedding is difficult.

Objective: To evaluate the morphologic characteristics of pulled out hair of TE. Read More

View Article and Full-Text PDF

Lichen Planus and Alopecia Areata Co-Localization.

Authors:
Sabha Mushtaq

Indian J Dermatol 2021 Jan-Feb;66(1):101-103

Department of Dermatology, Venereology and Leprology, Government Medical College, Jammu, Jammu and Kashmir, India. E-mail:

View Article and Full-Text PDF

Current insight into the functions of microRNAs in common human hair loss disorders: a mini review.

Hum Cell 2021 Apr 27. Epub 2021 Apr 27.

Section of Bioinformatics, Clinical Laboratory, Haukeland University Hospital, 5021, Bergen, Norway.

Alopecia areata (AA) and Androgenic alopecia (AGA) are the most common multifactorial hair loss disorders that have a serious psychological impact on the affected individuals, while frontal fibrosing alopecia (FFA) is comparatively less common. However, due to the unknown etiology and the effect of many adverse factors, the prognosis of these conditions is challenging to predict. Moreover, no approved therapy has been available to date to prevent or treat these disorders. Read More

View Article and Full-Text PDF

Gut microbiota characterization in Chinese patients with alopecia areata.

J Dermatol Sci 2021 Apr 15. Epub 2021 Apr 15.

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. Electronic address:

Background: The gut microbiota is known to play a key role in autoimmune diseases.

Objectives: To identify and compare the characteristics in the gut microbial composition of patients with alopecia areata (AA) and healthy controls (HCs).

Methods: In a cross-sectional discovery cohort, we enrolled 33 patients with AA and 35 HCs from the same geographic location in Shanghai, China. Read More

View Article and Full-Text PDF

Adenotonsillectomy may increase the risk of alopecia areata in childhood: a nationwide population-based cohort study.

J Am Acad Dermatol 2021 Apr 17. Epub 2021 Apr 17.

Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea; Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; Institute of Human Environment Interface Biology, Seoul National University College of Medicine, Seoul, Korea; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Korea. Electronic address:

View Article and Full-Text PDF

Baricitinib: From Rheumatoid Arthritis to COVID-19.

J Clin Pharmacol 2021 Apr 18. Epub 2021 Apr 18.

Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Baricitinib is a JAK1/2 inhibitor first approved for treating moderate to severe rheumatoid arthritis but later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases. There is a growing body of evidence, obtained from clinical trials and case reports, demonstrating clinical and paraclinical improvement in patients following administration of baricitinib including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, atopic dermatitis, alopecia areata, interferon-mediated auto-inflammatory diseases, graft versus host disease, diabetic kidney disease, and recently, coronavirus disease-19. However, despite overall encouraging results, many adverse effects have been observed in baricitinib-treated patients ranging from simple infections to increased risk of malignancies, particularly in long-term use. Read More

View Article and Full-Text PDF

Add-on effect of plum-blossom needling in alopecia areata: a qualitative evidence synthesis.

Ann Palliat Med 2021 Mar;10(3):3000-3008

Shanghai Skin Disease Hospital, Tongji Medical University, Shanghai, China.

Background: Alopecia areata (AA) is highly unpredictable, and therapeutic efficacy remains variable, which often prompts patients to seek alternative therapies. Plum-blossom needling has been widely used for thousands of years. The purpose of this meta-analysis was to critically evaluate the add-on effect of plum-blossom needling in AA and compared it with that of conventional treatment, which would provide guidance for AA therapy. Read More

View Article and Full-Text PDF

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.

Neurol Neuroimmunol Neuroinflamm 2021 05 9;8(3). Epub 2021 Apr 9.

From the Department of Neurology (L.R., S.P., M.P., T.R., H.W.), Institute of Translational Neurology, University Hospital of Münster, Germany; Department of Neurology (J.H., C.K., R.P.), University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Dermatology (W.S.), University Hospital Essen, University Duisburg-Essen, Essen, Germany; and Department of Neurology (M.K., S.G.M.), University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany.

Objective: To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.

Methods: We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin AE were identified. Read More

View Article and Full-Text PDF

Recent Insight on the Management of Lupus Erythematosus Alopecia.

Clin Cosmet Investig Dermatol 2021 30;14:333-347. Epub 2021 Mar 30.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Lupus erythematosus (LE) is a chronic autoimmune condition with a wide spectrum of clinical presentations. Alopecias, both non-scarring and scarring, frequently occur in the context of LE and can assume several different patterns. Furthermore, alopecia occurring with LE may be considered LE-specific if LE-specific features are present on histology; otherwise, alopecia is considered non-LE-specific. Read More

View Article and Full-Text PDF

Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.

JCI Insight 2021 Apr 8;6(7). Epub 2021 Apr 8.

Department of Dermatology and.

The Janus kinase/signal transducers and activators of transcription (JAK/STAT) are key intracellular mediators in the signal transduction of many cytokines and growth factors. Common γ chain cytokines and interferon-γ that use the JAK/STAT pathway to induce biological responses have been implicated in the pathogenesis of alopecia areata (AA), a T cell-mediated autoimmune disease of the hair follicle. We previously showed that therapeutic targeting of JAK/STAT pathways using the first-generation JAK1/2 inhibitor, ruxolitinib, and the pan-JAK inhibitor, tofacitinib, was highly effective in the treatment of human AA, as well as prevention and reversal of AA in the C3H/HeJ mouse model. Read More

View Article and Full-Text PDF

Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.

Mini Rev Med Chem 2021 Mar 25. Epub 2021 Mar 25.

State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization and Key Laboratory of Plant Resources and Chemistry of Arid Zone, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011. China.

The small-molecular inhibitors targeted JAks (JAK inhibitors), could modulate the cytokines-mediated signaling via JAK-STAT pathway, which plays a important role in immune regulation and cell proliferation. The JAK inhibitors are previously designed and synthesized to treat diseases involved with hematologic and immune system. Increasing evidence shows that they are quite effective in atopic dermatitis (AD), alopecia areata (AA), psoriasis, vitiligo, and other autoimmune-induced dermatologic conditions. Read More

View Article and Full-Text PDF

Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice.

Sci Adv 2021 Apr 2;7(14). Epub 2021 Apr 2.

Department of Dermatology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.

The interleukin-7 (IL-7) signaling pathway plays an important role in regulation of T cell function and survival. We detected overexpression of IL-7 in lesional skin from both humans and C3H/HeJ mice with alopecia areata (AA), a T cell-mediated autoimmune disease of the hair follicle. We found that exogenous IL-7 accelerated the onset of AA by augmenting the expansion of alopecic T cells. Read More

View Article and Full-Text PDF

Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata.

Int J Mol Sci 2021 Mar 5;22(5). Epub 2021 Mar 5.

Department of Cellular & Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.

Alopecia areata (AA) is regarded as a tissue-specific and cell-mediated autoimmune disorder. Regarding the cytokine balance, AA has been considered a type 1 inflammatory disease. On the other hand, AA often complicates atopic dermatitis (AD) and AD is regarded as type 2 inflammatory disease. Read More

View Article and Full-Text PDF

Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review.

J Clin Med 2021 Mar 3;10(5). Epub 2021 Mar 3.

Department of Dermatology, Ghent University Hospital, B-9000 Gent, Belgium.

The biologic era has greatly improved the treatment of Crohn's disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasculitis, skin cancer, and cutaneous infections. Read More

View Article and Full-Text PDF

Dysbiosis and Enhanced Beta-Defensin Production in Hair Follicles of Patients with Lichen Planopilaris and Frontal Fibrosing Alopecia.

Biomedicines 2021 Mar 7;9(3). Epub 2021 Mar 7.

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Clinical Research Center for Hair and Skin Science, Department of Dermatology, Venereology and Allergology, Charitéplatz 1, 10117 Berlin, Germany.

Despite their distinct clinical manifestation, frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) display similar histopathologic features. Aberrant innate immune responses to endogenous or exogenous triggers have been discussed as factors that could drive inflammatory cascades and the collapse of the stem cell niche. In this exploratory study, we investigate the bacterial composition of scalp skin and plucked hair follicles (HF) of patients with FFA, LPP and alopecia areata circumscripta (AAc), as well as healthy individuals, in relation to cellular infiltrates and the expression of defense mediators. Read More

View Article and Full-Text PDF

Psychiatric basics of alopecia areata in pediatric patients: Evaluation of emotion dysregulation, somatization, depression, and anxiety levels.

J Cosmet Dermatol 2021 Apr 2. Epub 2021 Apr 2.

Department of Dermatology, Inonu University Faculty of Medicine, Malatya, Turkey.

Background/objective: Alopecia areata (AA) is a skin disease characterized by sudden-onset hair loss. The relationship between psychiatric status and AA has not been fully elucidated. The aim of this study was to evaluate emotion dysregulation, somatization, depression, and anxiety levels in children and adolescents with AA. Read More

View Article and Full-Text PDF

Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.

Drug Des Devel Ther 2021 23;15:1285-1298. Epub 2021 Mar 23.

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Treatment of extensive or recalcitrant alopecia areata (AA) is a major clinical challenge. Even after thorough investigation of several medications, its treatment outcomes have remained unsatisfactory. While there is no US Food and Drug Administration-approved medication for AA yet, topical immunotherapy has been a well-documented treatment option. Read More

View Article and Full-Text PDF

Cell cycle regulation in human hair follicle dermal papilla cells using nonthermal atmospheric pressure plasma-activated medium.

Medicine (Baltimore) 2021 Apr;100(13):e25409

Department of Obstetrics and Gynecology, Kyung Hee University Medical Center, Seoul, Republic of Korea.

Abstract: Nonthermal atmospheric pressure (NAP) plasmas have recently been developed and have been used for wound healing, blood coagulation, and cancer therapy. NAP plasmas can induce either cell proliferation or cell death, depending on the dose. Due to their efficacy and application easily, plasma activated mediums (PAMs) have been used in human cells recently. Read More

View Article and Full-Text PDF